Julie Y. Crider
About
Julie Y. Crider is a scholar working on Molecular Biology, Pharmacology and Cellular and Molecular Neuroscience.
According to data from OpenAlex, Julie Y. Crider has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 12 papers in Pharmacology and 11 papers in Cellular and Molecular Neuroscience. Recurrent topics in Julie Y. Crider's work include Receptor Mechanisms and Signaling (15 papers), Inflammatory mediators and NSAID effects (10 papers) and Glaucoma and retinal disorders (8 papers). Julie Y. Crider is often cited by papers focused on Receptor Mechanisms and Signaling (15 papers), Inflammatory mediators and NSAID effects (10 papers) and Glaucoma and retinal disorders (8 papers). Julie Y. Crider collaborates with scholars based in United States, China and Canada. Julie Y. Crider's co-authors include Najam A. Sharif, Brenda Walker Griffin, Curtis R. Kelly, Gary W. Williams, Shouxi Xu, Peter G. Klimko, Terry L. Davis, Naj Sharif, Eduardo C. Alfonso and Barry A. Schlech and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, British Journal of Pharmacology and Investigative Ophthalmology & Visual Science.
In The Last Decade
Julie Y. Crider
36 papers receiving 1.1k citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Julie Y. Crider United States | 21 | 588 | 398 | 285 | 260 | 173 | 36 | 1.1k | ||
| Achim H.‐P. Krauss United States | 25 | 853 1.5× | 401 1.0× | 496 1.7× | 355 1.4× | 132 0.8× | 51 | 1.7k | ||
| A L Nieves Ireland | 19 | 275 0.5× | 201 0.5× | 407 1.4× | 190 0.7× | 123 0.7× | 31 | 1.1k | ||
| Shouxi Xu United States | 17 | 246 0.4× | 297 0.7× | 124 0.4× | 227 0.9× | 194 1.1× | 31 | 807 | ||
| Naj Sharif United States | 13 | 294 0.5× | 261 0.7× | 72 0.3× | 137 0.5× | 104 0.6× | 24 | 636 | ||
| D.F. Woodward United States | 12 | 100 0.2× | 223 0.6× | 393 1.4× | 99 0.4× | 112 0.6× | 26 | 856 | ||
| A M Bogardus United States | 7 | 117 0.2× | 255 0.6× | 333 1.2× | 57 0.2× | 119 0.7× | 8 | 682 | ||
| Yonju Ha United States | 20 | 182 0.3× | 542 1.4× | 45 0.2× | 63 0.2× | 124 0.7× | 38 | 1.0k | ||
| Qingjun Lu China | 18 | 229 0.4× | 319 0.8× | 140 0.5× | 29 0.1× | 171 1.0× | 42 | 916 | ||
| S. Lake Sweden | 11 | 141 0.2× | 310 0.8× | 96 0.3× | 49 0.2× | 73 0.4× | 28 | 652 | ||
| Siqi Xiong China | 16 | 264 0.4× | 509 1.3× | 54 0.2× | 33 0.1× | 95 0.5× | 56 | 1.0k |
Countries citing papers authored by Julie Y. Crider
Since
Specialization
Citations
This map shows the geographic impact of Julie Y. Crider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Y. Crider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Y. Crider more than expected).
Fields of papers citing papers by Julie Y. Crider
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Julie Y. Crider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Y. Crider. The network helps show where Julie Y. Crider may publish in the future.
Co-authorship network of co-authors of Julie Y. Crider
This figure shows the co-authorship network connecting the top 25 collaborators of Julie Y. Crider. A scholar is included among the top collaborators of Julie Y. Crider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Y. Crider. Julie Y. Crider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sharif, Naj, et al.. (2006). AL–34662: A Novel, Potent and Efficacious Ocular Hypotensive Serotonin–2 Receptor Agonist. Investigative Ophthalmology & Visual Science. 47(13). 2944–2944.
2.
Sharif, Najam A., Curtis R. Kelly, Julie Y. Crider, & Terry L. Davis. (2006). Serotonin-2 (5-HT 2 ) Receptor-Mediated Signal Transduction in Human Ciliary Muscle Cells: Role in Ocular Hypotension. Journal of Ocular Pharmacology and Therapeutics. 22(6). 389–401.
3.
Sharif, Najam A., Marsha A. McLaughlin, Curtis R. Kelly, et al.. (2006). Preclinical Pharmacology of AL-12182, a New Ocular Hypotensive 11-Oxa Prostaglandin Analog. Journal of Ocular Pharmacology and Therapeutics. 22(5). 291–309.
4.
Sharif, Naj, Curtis R. Kelly, Julie Y. Crider, & Michelle Senchyna. (2005). RT–PCR Mapping of Serotonin Receptor Subtype mRNAs in Human Ciliary Body and Trabecular Meshwork. Investigative Ophthalmology & Visual Science. 46(13). 3688–3688.
5.
Alfonso, Eduardo C. & Julie Y. Crider. (2005). Ophthalmic Infections and Their Anti-infective Challenges. Survey of Ophthalmology. 50(6). S1–S6.
6.
Sharif, Naj, Gary W. Williams, Julie Y. Crider, Shouxi Xu, & Terry L. Davis. (2004). Molecular Pharmacology of the DP/EP 2 Class Prostaglandin AL-6598 and Quantitative Autoradiographic Visualization of DP and EP 2 Receptor Sites in Human Eyes. Journal of Ocular Pharmacology and Therapeutics. 20(6). 489–508.
7.
Sharif, Naj, Curtis R. Kelly, Julie Y. Crider, & Michelle Senchyna. (2003). Human Ciliary Muscle and Trabecular Meshwork Cells Express Functional Serotonin-2 (5-HT2) Receptors Coupled to Phosphoinositide Turnover and [Ca2+]i Mobilization. Investigative Ophthalmology & Visual Science. 44(13). 2084–2084.
8.
Sharif, Najam A., Curtis R. Kelly, Julie Y. Crider, Gary W. Williams, & Shouxi Xu. (2003). Ocular Hypotensive FP Prostaglandin (PG) Analogs: PG Receptor Subtype Binding Affinities and Selectivities, and Agonist Potencies at FP and Other PG Receptors in Cultured Cells. Journal of Ocular Pharmacology and Therapeutics. 19(6). 501–515.
9.
Sharif, Naj, Julie Y. Crider, Shahid Husain, et al.. (2003). Human Ciliary Muscle Cell Responses to FP-Class Prostaglandin Analogs: Phosphoinositide Hydrolysis, Intracellular Ca 2+ Mobilization and MAP Kinase Activation. Journal of Ocular Pharmacology and Therapeutics. 19(5). 437–455.
10.
Crider, Julie Y. & Najam A. Sharif. (2002). Adenylyl Cyclase Activity Mediated by β -Adrenoceptors in Immortalized Human Trabecular Meshwork and Non-Pigmented Ciliary Epithelial Cells. Journal of Ocular Pharmacology and Therapeutics. 18(3). 221–230.
11.
Sharif, Najam A., Curtis R. Kelly, & Julie Y. Crider. (2002). Agonist Activity of Bimatoprost, Travoprost, Latanoprost, Unoprostone Isopropyl Ester and Other Prostaglandin Analogs at the Cloned Human Ciliary Body FP Prostaglandin Receptor. Journal of Ocular Pharmacology and Therapeutics. 18(4). 313–324.
12.
Crider, Julie Y. & Najam A. Sharif. (2001). Functional Pharmacological Evidence for EP 2 and EP 4 Prostanoid Receptors in Immortalized Human Trabecular Meshwork and Non-Pigmented Ciliary Epithelial Cells. Journal of Ocular Pharmacology and Therapeutics. 17(1). 35–46.
13.
Sharif, Najam A., Shouxi Xu, Julie Y. Crider, Marκ McLaughlin, & Terry L. Davis. (2001). Levobetaxolol (Betaxon™) and Other β -Adrenergic Antagonists: Preclinical Pharmacology, IOP-Lowering Activity and Sites of Action in Human Eyes. Journal of Ocular Pharmacology and Therapeutics. 17(4). 305–317.
14.
Sharif, Najam A., Julie Y. Crider, Shouxi Xu, & Gary W. Williams. (2000). Affinities, Selectivities, Potencies, and Intrinsic Activities of Natural and Synthetic Prostanoids Using Endogenous Receptors: Focus on DP Class Prostanoids. Journal of Pharmacology and Experimental Therapeutics. 293(2). 321–328.
15.
Crider, Julie Y., Brenda Walker Griffin, & Najam A. Sharif. (2000). Endogenous EP4prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: pharmacological characterization. Prostaglandins Leukotrienes and Essential Fatty Acids. 62(1). 21–26.
16.
Crider, Julie Y., Brenda Walker Griffin, & Naj Sharif. (1998). Prostaglandin-Stimulated Adenylyl Cyclase Activity Via a Pharmacologically Defined EP 2 Receptor in Human Nonpigmented Ciliary Epithelial Cells. Journal of Ocular Pharmacology and Therapeutics. 14(4). 293–304.
17.
Crider, Julie Y., Brenda Walker Griffin, Shouxi Xu, & Najam A. Sharif. (1998). Use of a semi-automated, robotic radioimmunoassay to measure cAMP generated by activation of DP-, EP2-, and IP-prostaglandin receptors in human ocular and other cell types. Prostaglandins Leukotrienes and Essential Fatty Acids. 59(1). 77–82.
18.
Sharif, Najam A., Julie Y. Crider, Brenda Walker Griffin, Terry L. Davis, & W E Howe. (1997). Pharmacological Analysis of Mast Cell Mediator and Neurotransmitter Receptors Coupled to Adenylate Cyclase and Phospholipase C on Immunocytochemically-Defined Human Conjunctival Epithelial Cells. Journal of Ocular Pharmacology and Therapeutics. 13(4). 321–336.
19.
Crider, Julie Y., Thomas Yorio, Najam A. Sharif, & Brenda Walker Griffin. (1997). The Effects of Elevated Glucose on Na + /K + -ATPase of Cultured Bovine Retinal Pigment Epithelial Cells Measured by a New Nonradioactive Rubidium Uptake Assay a,b. Journal of Ocular Pharmacology and Therapeutics. 13(4). 337–352.
20.
Tsin, Andrew, Brenda Walker Griffin, Nathan L. Mata, et al.. (1993). Vitamin A Homeostasis in the Diabetic Rat.. Journal of Clinical Biochemistry and Nutrition. 15(1). 23–31.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Achim H.‐P. Krauss Breakdown of academic impact, for papers by A L Nieves Breakdown of academic impact, for papers by Shouxi Xu Breakdown of academic impact, for papers by Naj Sharif Breakdown of academic impact, for papers by D.F. Woodward Breakdown of academic impact, for papers by A M Bogardus Breakdown of academic impact, for papers by Yonju Ha Breakdown of academic impact, for papers by Qingjun Lu Breakdown of academic impact, for papers by S. Lake Breakdown of academic impact, for papers by Siqi Xiong